AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03215355
Drug: Primovist
DrugBank: Gadoxetic acid (DB08884)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primovist is currently a drug marketed for MRI. In this study it will be administered intravenously at 4 times what it is quoted for MRI to enhance the different imaging modality (CBCT) to improve the accuracy of liver SBRT. Although liver SBRT usually consists of 5 treatments, contrast will only be administered during the first treatment.~Consulting Health Canada and Bayer HealthCare Canada (the drug manufacturer) deemed this use off label dosing which in Canada is at the discretion of the physician. Based on preliminary imaging testing, and a review of toxicity literature for this drug, the administration for this specific use was deemed appropriate to give adequate image quality, while simultaneously maintaining patient safety.
Trial: NCT00028886
Drug: melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00028886
Drug: thalidomide
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00028886
Drug: vincristine sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03930992
Drug: Colaren in HIV positive
RxNorm normalized name: HIV Integrase Inhibitor
DrugBank: HIV Integrase Inhibitor (DB16114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 Arm (HIV+): will receive Zoledronic acid 4mg and colaren ® (vitamin D, magnesium, phosphate, calcium).
Trial: NCT03930992
Drug: Colaren in HIV negative
RxNorm normalized name: GLYCERIN NEGATIVE CONTROL
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 Arm (HIV-): will receive Zoledronic acid 4mg and colaren ® (vitamin D, magnesium, phosphate, calcium).
Trial: NCT00148447
Drug: escitalopram
RxNorm normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03261349
Drug: Ledipasvir and sofosbuvir
RxNorm normalized name: Ledipasvir and Sofosbuvir Tablets
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: To assess whether Harvoni® (ledipasvir and sofosbuvir) could eradicate HCV and lead to durable complete remission of these lymphomas.
Trial: NCT00003589
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003589
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003589
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT04246723
Drug: Narlaprevir
RxNorm normalized name: narlaprevir
DrugBank: Narlaprevir (DB14760)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg oval shaped, concave, yellow film-coated tablets taken as 200 mg per os once daily. 28 tabs/36 tabs/ 56 tabs in bottle.
Trial: NCT04246723
Drug: Ritonavir
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 100 mg tablets taken as 100 mg per os once daily. 30 tablets in bottle
Trial: NCT04246723
Drug: Sofosbuvir
RxNorm normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400 mg yellow, capsule-shaped film-coated tablets debossed with GSI on one side and 7977 on the other side, taken as 400 mg per os once daily. 28 tablets in bottle.
Trial: NCT03343600
Drug: Imatinib
RxNorm normalized name: Imatinib
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Imatinib 100 mg/tablet, 2 tablets daily
Trial: NCT04906434
Drug: 60mg ABSK-011capsule
RxNorm normalized name: ABSK-012
DrugBank: ABSK-012 (DB18035)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three 20mg capsules,QD for oral administration
Trial: NCT04906434
Drug: 120mg ABSK-011capsule
RxNorm normalized name: ABSK-012
DrugBank: ABSK-012 (DB18035)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One 20mg capsule and one 100mg capsule,QD for oral administration
Trial: NCT04906434
Drug: 180mg ABSK-011capsule
RxNorm normalized name: ABSK-012
DrugBank: ABSK-012 (DB18035)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One 100mg capsule and four 20mg capsules,QD for oral administration
Trial: NCT04906434
Drug: 240mg ABSK-011capsule
RxNorm normalized name: ABSK-012
DrugBank: ABSK-012 (DB18035)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two 100mg capsules and two 20mg capsules,QD for oral administration
Trial: NCT04906434
Drug: 320 mg ABSK-011capsule
RxNorm normalized name: ABSK-012
DrugBank: ABSK-012 (DB18035)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three 100mg capsule and one 20mg capsule,QD for oral administration
Trial: NCT03437226
Drug: Levosimendan 2.5 MG/ML
RxNorm normalized name: levosimendan 2.5 MG/ML
DrugBank: Levosimendan (DB00922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosimendan Arm: 1 x 5 ml (1 vial) of levosimendan infusion concentrate is added to one 250 ml infusion bag of 5% glucose or 0.9% NaCl in diabetic patients.
Trial: NCT03415555
Drug: Oxycodone
RxNorm normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Each patient, before the end of surgery, will be administered i.v. 0.1 mg of oxycodone. PCA with oxycodone (1mg/mL) will be utilized during the postoperative period: 5-minute interval.
Trial: NCT03415555
Drug: paracetamol
RxNorm normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paracetamol will be given i.v. every 6 hours.
Trial: NCT00948740
Drug: vitamin D (ergocalciferol)
RxNorm normalized name: Vitamin D (Ergocalciferol)
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intervention is oral ergocalciferol 50,000 IU per week for 8 weeks
Trial: NCT03585140
Drug: Adapalene 0.1% Gel
RxNorm normalized name: ADAPALENE 0.1% GEL,TOP
DrugBank: Adapalene (DB00210)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adapalene 0.1% gel daily at night for 12 weeks, applied on the face, chest and back.
Trial: NCT04906434
Drug: 400mg ABSK-011capsule
RxNorm normalized name: ABSK-012
DrugBank: ABSK-012 (DB18035)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four 100mg capsules,QD for oral administration
Trial: NCT01576640
Drug: NRT
RxNorm normalized name: ALUMINUM CHLOROHYDRATE 20 g in 100 g TOPICAL STICK [CLARISSE ANTIPERSPIRANT DEODORANRT]
DrugBank: Aluminum sulfate (DB11239)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received nicotine replacement therapy in the form of nicotine gum/lozenge and nicotine patch
Trial: NCT01576640
Drug: Bupropion SR 150mg bid
RxNorm normalized name: bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects were given bupropion SR 150 mg bid throughout the course of the study.
Trial: NCT02091180
Drug: Mannitol
RxNorm normalized name: Mannitol
DrugBank: Mannitol (DB00742)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5g/kg of 20% intravenous (i.v.) mannitol infusion over 10 minutes immediately before induction of anesthesia
Trial: NCT02091180
Drug: Control
RxNorm normalized name: Control
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline infusion
Trial: NCT00649454
Drug: Glipizide and Metformin HCl Tablets 5 mg/500 mg
RxNorm normalized name: glipizide / metformin hydrochloride Oral Tablet
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 5/500mg, single dose fasting
Trial: NCT03291314
Drug: Axitinib
RxNorm normalized name: Axitinib
DrugBank: Axitinib (DB06626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1. Axitinib, a VEGFR-specific small molecule tyrosine kinase inhibitor (Tki) has demonstrated anti-tumor activity when evaluated as a mono-therapy and in combination with lomustine for the treatment of patients with recGB (EudraCT 2011-000900-16) \[7\].
Trial: NCT03291314
Drug: Avelumab
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2. Avelumab (MSB00107; anti-PD-L1) is a fully human anti-PD-L1 IgG1 monoclonal antibody (mAb) that has demonstrated anti-tumor activity in several tumor types.
Trial: NCT03893045
Drug: ferumoxytol
RxNorm normalized name: Ferumoxytol
DrugBank: Ferumoxytol (DB06215)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Each 20 mL single-use vial contains 17 mL of ferumoxytol that consists of iron at a concentration of 30 mg Fe/mL, coated with polyglucose sorbitol carboxymethylether and formulated with mannitol, at a concentration of 44 mg/mL, in a black to reddish brown sterile, aqueous, colloidal, isotonic solution
Trial: NCT03893045
Drug: Iron sucrose
RxNorm normalized name: Iron Sucrose
DrugBank: Iron sucrose (DB09146)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each mL contains 20 mg of elemental iron as iron sucrose in water for injection. The 5 mL single-use vial contains 100 mg of iron per 5 mL. The drug product contains approximately 30% sucrose (300 mg/mL).
Trial: NCT03625531
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Letrozole will be started on day 3 to day 7 of the spontaneous period or a withdrawal bleeding following progestin. If there is response with ovulation, this dose will be maintained. In those with no ovulatory response, letrozole tablets of the next ovulation cycle will be take on the day 28 of the menstrual cycle and the letrozole dose will be increased to 5 mg (2 pills) a day for 5 days. If there is still no response, the dose will be increased to 7.5 mg per day for 5 days in the next cycle. The maximum daily dose of letrozole will be 7.5 mg (3 pills) daily for five days.
Trial: NCT03625531
Drug: Placebo letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo letrozole will be given in the same way as letrozole. Women will receive 1 tablet a day of placebo letrozole from the day 3 to day 7 of the menstrual cycle and placebo letrozole dose will be increased 2 tablets a day in the next cycle if there is no response. The maximum daily dose of placebo letrozole will be 3 tablets daily for five days.
Trial: NCT01767584
Drug: Cephalexin 1g tablets
RxNorm normalized name: Cephalexin
DrugBank: Cephalexin (DB00567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference product
Trial: NCT01767584
Drug: Cephalexin 1g tablets
RxNorm normalized name: Cephalexin
DrugBank: Cephalexin (DB00567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test product
Trial: NCT01271140
Drug: Insulin
RxNorm normalized name: Insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous insulin clamp at a rate of 2 mlu/kg/hr. In adition a titrating dose of 20% dextrose aiming to a blood glucose level of 4 - 5.5 mmol/l.
Trial: NCT00544934
Drug: GLY-230
RxNorm normalized name: Gly
DrugBank: Glycine (DB00145)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 125, 250 0r 375 mg bid for 14 days
Trial: NCT01059383
Drug: Esomeprazole 20 mg
RxNorm normalized name: esomeprazole 20 MG
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 capsule, orally, once daily 30-60 min. before dinner
Trial: NCT02673229
Drug: Collagenase Santyl
RxNorm normalized name: collagenase Topical Ointment [Santyl]
DrugBank: Collagenase clostridium histolyticum (DB00048)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A sterile, enzymatic debriding agent which contains 250 collagenase units per gram of white petrolatum, United States Pharmacopeia (USP).
Trial: NCT02673229
Drug: Bacitracin
RxNorm normalized name: Bacitracin
DrugBank: Bacitracin (DB00626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One gram is equal to 500 bacitracin units; one unit of bacitracin is equivalent to 0.026 milligrams.
Trial: NCT00499109
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GD Group: 40 mg/m\^2 on days 1 and 8, every 21 days~DCb Group: 75 mg/m\^2 on day 1~DV Group: 50 mg/m\^2 on days 1 and 15, every 28 days
Trial: NCT00499109
Drug: Vinorelbine
RxNorm normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DV Group: 35 mg/m\^2 on days 1 and 15
Trial: NCT00499109
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: GCb Group: Area under the curve (AUC) 5 on day 1, every 21 days~DCb Group: AUC 6 on day 1, every 21 days~Control Arm: Patients received up to 6 cycles, and no maintenance therapy was allowed.
Trial: NCT00499109
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: GCb Group: 1,250 mg/m\^2 on days 1 and 8~GD Group: 1,250 mg/m\^2 on days 1 and 8~Control Arm: Patients received up to 6 cycles, and no maintenance therapy was allowed.
Trial: NCT01943552
Drug: ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ipratropium bromide
Trial: NCT00003719
Drug: irinotecan hydrochloride
RxNorm normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00084149
Drug: Abacavir sulfate, Lamivudine, and Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: antiretroviral therapy
Trial: NCT00084149
Drug: Lopinavir/Ritonavir
RxNorm normalized name: LOPINAVIR/RITONAVIR
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: antiretroviral therapy
Trial: NCT04477057
Drug: HS-10241
RxNorm normalized name: HS-CoM
DrugBank: Coenzyme M (DB09110)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HS-10241 is a tablet in the form of 100 mg, oral, once daily.
Trial: NCT04274803
Drug: Conventional therapy of antiphospholipis syndrome
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: the conventional basic treatment of APS (Dual low dose aspirin (LDA) (Ezacard 75mg) once daily and Low molecular weight heparin (LMWH) (clexane 4000 IU) injection once daily.
Trial: NCT03230292
Drug: Bimekizumab
RxNorm normalized name: bimekizumab
DrugBank: Bimekizumab (DB12917)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Bimekizumab will be administered subcutaneously in 2 different doses.
Trial: NCT03118830
Drug: Triptorelin
RxNorm normalized name: triptorelin
DrugBank: Triptorelin (DB06825)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: daily SC injection of Triptorelin 0.1 mg started at day 21 of the cycle prior to stimulation cycle and continued till the day of hCG triggering.
Trial: NCT03118830
Drug: cetrorelix
RxNorm normalized name: Cetrorelix
DrugBank: Cetrorelix (DB00050)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flexible GnRH antagonist protocol was done with daily s.c administration of cetrorelix 0.25 mg started when one or more of the following criteria were achieved: (i) one or more follicle reached 14 mm diameter; (ii) The level of serum E2 reached 600 pg/ml; and (iii) The level of serum LH levels reached 10 IU/l .
Trial: NCT04302064
Drug: Eplontersen
RxNorm normalized name: EPLONTERSEN
DrugBank: Eplontersen (DB16199)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eplontersen administered SC
Trial: NCT00830193
Drug: N-acetylcysteine
RxNorm normalized name: N-acetylcysteine
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medication packages were prepared and dispensed by pharmacy and included three premixed and prepackaged minibags containing either 5 g of NAC or placebo in 100 cc D5W (pre-CT dose) or 2.5 g of NAC or placebo in 50 cc D5W (post-CT doses).
Trial: NCT01475162
Drug: Tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab will be administered intravenously at a dose of 8 mg/kg once every three weeks for three doses. After Day 56 doses may be decreased to 4mg/kg once every three weeks depending on GVHD response.
Trial: NCT03752723
Drug: GX-I7
RxNorm normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.m.
Trial: NCT03752723
Drug: Pembrolizumab(KEYTRUDA®)
RxNorm normalized name: pembrolizumab Injection [Keytruda]
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: i.v.
Trial: NCT00117689
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Between Day 3 the last dose of Thymoglobulin
Trial: NCT00117689
Drug: Mycophenolate Mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: for at least 1 month posttransplant
Trial: NCT02282904
Drug: Sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: For pediatric patients: Begin sirolimus 1 mg/m2 PO q4h for 3 doses, then 1 mg/m2 once a day (QD). For adult patients, begin sirolimus 5 mg PO q4h for 3 doses, then 5 mg once a day (QD).~Doses may be adjusted to maintain trough levels between 8-14 ng/ml. Recipients will take sirolimus from Day +5 to at least Day 100 (minimum).
Trial: NCT02282904
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/m2 over 30 minutes Day -6 through Day -2
Trial: NCT02282904
Drug: Busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Busulfan 3.2 mg/kg IV once daily over 2-3 hours Day -4,-3,-2
Trial: NCT00560495
Drug: ammonium tetrathiomolybdate
RxNorm normalized name: Ammonium tetrathiomolybdate
DrugBank: Ammonium tetrathiomolybdate (DB17641)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 times daily for up to 3 weeks
Trial: NCT00442325
Drug: Atorvastatin (Lipitor)
RxNorm normalized name: atorvastatin Oral Tablet [Lipitor]
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04242056
Drug: 18F-PM-PBB3
RxNorm normalized name: (18F)-Fluoride
DrugBank: Fluoride ion F-18 (DB09398)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18F-PM-PBB3 brain PET studies will be conducted for 38 subjects. Dynamic PET/MRI studies will be collected by PET/MRI scanner for 100 minutes (4×15 s, 8×30 s, 960 s, 2×180 s, 8300 s, 3×600 s). Volumes of interest (VOIs) will be delineated from corresponding MR images by manual including bilateral frontal, parietal, mesial temporal, lateral temporal, hippocampal, occipital, anterior cingulate, posterior cingulate, cerebellum areas, and genu region of white matter. The DVRs will be computed from Logan graphic analysis by using cerebellum as reference input.~SUVR of every cortical VOI to the gray matter of cerebellum will be calculated from nine 10-min dynamic image sets.
Trial: NCT02896270
Drug: Valproic Acid
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The concomitant immunosuppressive regimen is to be reduced at the discretion of the investigators. It is suggested to lower immunosuppressive therapy only in valproic acid target trough levels have been attained.
Trial: NCT00514020
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 500 ml D5W through a vein over 2 hours on days 1 and 15.
Trial: NCT01092962
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1200mg/m²/jour in two divided doses during 18 months
Trial: NCT04560894
Drug: SCT-I10A
RxNorm normalized name: Immunoglobulin g4 (226-proline), anti-(human programmed cell death 1) (human-mus musculus monoclonal sct-i10a .gamma.4-chain), disulfide with human-mus musculus monoclonal sct-i10a .kappa.-chain, dimer
DrugBank: Finotonlimab (DB18859)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants receive SCT-I10A intravenously，200mg，d1，Q3w
Trial: NCT04560894
Drug: Sorafenib 200mg
RxNorm normalized name: SORAFENIB 200MG TAB
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants receive sorafenib orally，400mg bid
Trial: NCT02418104
Drug: CHS-1701
RxNorm normalized name: CHS-828
DrugBank: CHS-828 (DB12980)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02418104
Drug: Pegfilgrastim (Neulasta)
RxNorm normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT04705948
Drug: Magnesium sulfate versus ketamine
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate versus ketamine for of post-operative sore throat after endotracheal intubation
Trial: NCT04334564
Drug: Ginkgo biloba capsule
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo biloba capsule may improve visual function of primary open-angle glaucoma by repairing of the optic nerve.
Trial: NCT00828789
Drug: Efavirenz; Tenofovir disoproxil fumarate; Telaprevir
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02678884
Drug: 18-F FDG
RxNorm normalized name: 18-F FDG
DrugBank: Fludeoxyglucose (18F) (DB09502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients enrolled in this study will receive 2 PET Scans: One prior to Radiation, and one during Radiation.
Trial: NCT04639817
Drug: Levofloxacin
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levofloxacin administration
Trial: NCT04639817
Drug: trimethoprim-sulfamethoxazole
RxNorm normalized name: sulfamethoxazole / trimethoprim
DrugBank: Trimethoprim (DB00440)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trimethoprim-sulfamethoxazole administration
Trial: NCT03283436
Drug: Bupivacaine Hydrochloride 0.25% Injection Solution
RxNorm normalized name: Bupivacaine Hydrochloride 0.25% Injection Solution
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mL of 0.25% bupivacaine hydrochloride (2.5 mg/mL = 25 mg)
Trial: NCT02049138
Drug: Upadacitinib
RxNorm normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablet taken orally